All services Oncology Virology Men's Health Fertility Gastro Customer Handbook (PDF)
Proclarix Stockholm3 Prostatype Bladder EpiCheck EarlyCDT Lung Genetic Testing

Oncology testing

Prostate cancer screening

Cambridge Clinical Laboratories - Lab 3 - equipment.jpg
 

Stockholm3

 

An advanced screening test for early detection of aggressive prostate cancer, using blood protein markers, genetics and clinical data.

How does stockholm3 work?

Stockholm3 is a blood test for the early detection of prostate cancer. It measures the levels of 5 protein markers and the presence of multiple genetic markers. The result is a risk score that indicates the risk of prostate cancer that is likely to spread. With elevated risk, a referral to a urologist for further examination is recommended and with low or normal risk a new test within two to six years.

Stockholm3 has been used in clinical practice in Sweden, Norway and Finland since 2019, it is included in European and American prostate cancer guidelines and has been tested in trials on over 75,000 men. Several major healthcare providers in Europe are using Stockholm3 instead of PSA screening.

“Stockholm3 is a more precise test compared to PSA”

Early detection is the key for the successful detection of prostate cancer. There is evidence showing that 30-50% of all aggressive prostate cancers are found in men with normal PSA results (below 3ng/ml). Stockholm3 has major advantages compared to PSA:

·       Stockholm3 finds high-risk men with normal PSA results.

·       Stockholm3 finds twice as many men with aggressive prostate cancer requiring treatment compared to PSA in clinical routine.

“Stockholm3 reduces over-detection and unnecessary procedures/anxiety”

It's crucial to understand that many men have benign prostate cancer tumours that won't pose a threat during their lifetime. Using Stockholm3 before MRI minimises over-detection by identifying men at low risk of harmful prostate cancer, even if their PSA levels are elevated.

For many men, this will mean avoiding unnecessary and uncomfortable procedures like a prostate biopsy as well as the associated stress and worry associated with these procedures and waiting for results. Stockhom3 has been shown to cut the number of unnecessary biopsies in half compared to PSA in clinical practice.

“Based on evidence from the large-scale scientific studies”

Stockholm3 has been developed by researchers at the Karolinska Institutet and evaluated and validated on over 75,000 men in Sweden, Norway Finland, Germany and Switzerland. A large validation study has recently been conducted in the USA. Over 45 scientific articles have been published about Stockholm3, many in leading scientific journals such as The Lancet Journal and European Urology. Stockholm3 has received awards for its research from the European Association of Urology three years in a row, in 2021, 2022, and 2023. The latest study was published in The Lancet Oncology and awarded the European Association of Urology (EAU) "Prostate Cancer Research Award 2022". More about Stockholm3 publications here: https://www.a3p.com/en/publications/

Endorsed by Prostate Matters

Prostate Matters is a not for profit organisation committed to providing free information about prostate issues from leading Clinical Authorities.

They have endorsed Stockholm3 and provide further information about the test on their site here.

The charity has also worked with Professor Raj Persad, one of the leading consultants providing Stockholm3 in the UK, to produce an overview of how Stockholm3 is being used in clinical practice.

what do the results tell you?

The result from Stockholm3 is a risk score that indicates the risk of aggressive prostate cancer as being either: elevated risk, normal risk or low risk. Stockholm3 also provides clear treatment recommendations which makes it easier for the treating doctor to make a decision on potential further actions. With elevated risk, a referral to a urologist for further examination is recommended, and with low or normal risk a new test within two to six years is recommended. Nearly half of the men aged 50 to 70 years have a low risk profile and do not need to take a new test until after six years.

The intended target group for Stockholm3 is men between the ages of 45 and 74.

where to access stockholm3

Order online and attend a clinic near you:

Via a specialist consultant:

You can access Stockholm3 through a specialist prostate consultant, by booking in for a consultation where the consultant will go through all your clinical data, family history, and discuss any concerns you have. They will take your blood sample and usually book a follow-up consultation to discuss the results. They will be able to guide any further monitoring or investigation, if required. The consultants who provide Stockholm3 upon request are below:

Via a Private GP:

Via a clinic:

You can book in for a Stockholm3 test at a clinic local to you, where your blood sample will be taken. A short appointment may be required to ensure all your clinical data is collected. The clinic provider will then deliver your results via email, phone call or in-person appointment. The report containing your results describes what the risk score score means. You can book in to discuss this result with a GP or consultant if required/preferred.

 (UK-wide locations coming soon…)